Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:34:26 ON 14 JUL 2009

=> File .Gerry2MBCE
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'MEDLINE' ENTERED AT 09:34:48 ON 14 JUL 2009

FILE 'BIOSIS' ENTERED AT 09:34:48 ON 14 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 09:34:48 ON 14 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:34:48 ON 14 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> D Hist

(FILE 'HOME' ENTERED AT 09:34:26 ON 14 JUL 2009)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 09:34:48 ON 14 JUL 2009

=> S ((Williams A/au) OR (Sereda T/au)) AND ((human growth factor) OR hGH)
L1 1 ((WILLIAMS A/AU) OR (SEREDA T/AU)) AND ((HUMAN GROWTH FACTOR) OR HGH)

=> D Ibib abs L1

L1 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001420775 EMBASE
TITLE: HIV patient acceptance of a needle-free device (SeroJet®) for administering recombinant human growth hormone in the treatment of HIV infection-associated cachexia.
AUTHOR: Murray, F.T., Dr. (correspondence); Muurahainen, N.; Gertner, J.M.; Williams, A.; Santos, G.; Scheperle, M.; Richmond, G.; Finkelstein, J.; Nebiolo, L.; Gaccione, P.
CORPORATE SOURCE: Serono Laboratories, Inc., 100 Longwater Circle, Norwell, MA 02061, United States.
SOURCE: Today's Therapeutic Trends, (2001) Vol. 19, No. 4, pp. 283-295.
Refs: 20
ISSN: 0741-2320 CODEN: TTTRDH
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
006 Internal Medicine

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Dec 2001
Last Updated on STN: 20 Dec 2001

AB A randomized, two-way crossover study of recombinant human growth hormone (somatropin; r-hGH [Serostim®]) 6 mg in 0.5 ml administered subcutaneously either by syringe or needle-free device (SeroJet®) injection was conducted in 78 HIV-positive adult male (65) and female (13) subjects with cachexia (wasting), to assess the acceptability of growth hormone administered using these two alternative methods of injection. In general, the study findings demonstrated similar results on the descriptive and comparative questionnaires for the needle with syringe and needle-free groups during the entire 14 days of growth hormone dosing. Descriptive questionnaires relating to hurt or pain, wetness, redness, and anxiety showed minimal responses in over 90% of patients, and in over 85% of patients with regard to stinging, with both the needle and syringe and needle-free administration. In addition, analysis of responses to comparative questions relating to ease of use, convenience, anxiety, pain and overall preference indicated no statistically significant differences between needle and needle-free administration. Male sex and a previous history of subcutaneous and intramuscular needle injections favored syringe with needle injection over needle-free administration, though not statistically significantly. In conclusion, needle-free administration of r-hGH with SeroJet® was well tolerated, as safe as conventional needle injection, and at least as acceptable to patients. The use of SeroJet® for Serostim® growth hormone administration may diminish the potential for accidental needlestick injury and/or transmission of blood-borne infection with no increase in adverse reactions, thus making this method of injection an advance for patients with communicable diseases who require treatment with injectable medications.

=> Log off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:38:32 ON 14 JUL 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE'
AT 09:42:32 ON 14 JUL 2009
FILE 'MEDLINE' ENTERED AT 09:42:32 ON 14 JUL 2009
FILE 'BIOSIS' ENTERED AT 09:42:32 ON 14 JUL 2009

FILE 'CAPLUS' ENTERED AT 09:42:32 ON 14 JUL 2009

FILE 'EMBASE' ENTERED AT 09:42:32 ON 14 JUL 2009

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.11	24.33

```
=> S ((growth hormone) OR Somatotropin OR Somatropin OR GH) (S) (Formulation OR
composition) (S) ((Polyethylene glycol) OR PEG)
L2          37 ((GROWTH HORMONE) OR SOMATOTROPIN OR SOMATROPIN OR GH) (S) (FORM
               ULATION OR COMPOSITION) (S) ((POLYETHYLENE GLYCOL) OR PEG)

=> DUP Rem L2
PROCESSING COMPLETED FOR L2
L3           34 DUP REM L2 (3 DUPLICATES REMOVED)
                ANSWER '1' FROM FILE MEDLINE
                ANSWERS '2-34' FROM FILE CAPLUS

=> D Ti L3 1-34

L3   ANSWER 1 OF 34     MEDLINE on STN                  DUPLICATE 1
TI   Controlled release of growth hormone from thermosensitive triblock
     copolymer systems: In vitro and in vivo evaluation.

L3   ANSWER 2 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions containing human growth hormone

L3   ANSWER 3 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Human growth hormone formulations

L3   ANSWER 4 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Streptoverticillium transglutaminase variants with improved specificity
     towards human growth hormone, and use for the preparation of
     pharmaceutical compositions

L3   ANSWER 5 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Ceramic implant composition comprising bioactive glass particles in
     glycerol/polyethylene glycol carrier aqueous solution, for filling bone
     defects

L3   ANSWER 6 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Sustained-release fine particle compositions and their manufacture

L3   ANSWER 7 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions containing the conjugates of polyethylene
     glycol with oligopeptide and proteins

L3   ANSWER 8 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Human growth hormone patch formulations

L3   ANSWER 9 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Liquid formulation comprising human growth hormone whose deamidation and
     agglutination are minimized

L3   ANSWER 10 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Stable growth hormone liquid formulation

L3   ANSWER 11 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   A pharmaceutical composition comprising a recombinant nonglycosylated
     immunoglobulin Fc region conjugated to a therapeutic protein as a drug
     carrier

L3   ANSWER 12 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   A pharmaceutical composition comprising aglycosylated IgG Fc fragment as a
     drug carrier, and method for the preparation thereof

L3   ANSWER 13 OF 34  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Long-acting modified proteins used in sustained release formulations for
     reduced clearance
```

L3 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Liquid human growth hormone formulation containing polyethylene glycol

L3 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions and methods for enhanced mucosal delivery of growth hormone

L3 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone conjugated with biocompatible polymer

L3 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Composition for stabilized liquid formulation of human growth hormone which minimizes deamidation, polymer formation and oxidative dissociation of human growth hormone(hGH)

L3 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Novel Long-Acting Crystal Formulation of Human Growth Hormone

L3 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Methods and compositions for the preparation of human growth hormone (hCG) glycosylation mutants with reduced immunogenicity, and therapeutic uses thereof

L3 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone crystals and methods for preparing them

L3 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Biodegradable pharmaceutical composition enabling sustained release of human growth hormone and microsphere thereof

L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained release formulations for growth hormone secretagogues

L3 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Optimization of the molecular properties and formulation of proteins delivered by inhalation by pegylation or glycosylation

L3 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI A somatotropin composition with improved syringeability

L3 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained releasing composition comprising somatotropin

L3 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Wound healing compositions containing cell culture medium and growth hormones

L3 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained-release protein formulations with PEG and triacetin

L3 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Implantable composition for the controlled release of somatotropin

L3 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Oral compositions of proteinaceous medicaments

L3 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Injection formulations containing therapeutic peptides and hormones

L3 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Improved high-impact, antistatic, rubber-modified styrene polymer

compositions

L3 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Toilet-cleaning compositions containing polyethylene glycols and ethylene oxide-propylene oxide copolymers

L3 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Water-based ink compositions for ball point pens

L3 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Long-acting somatostatin composition

=> D ibib abs L3 1-34

L3 ANSWER 1 OF 34 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2008138257 MEDLINE
DOCUMENT NUMBER: PubMed ID: 18036752
TITLE: Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation.
AUTHOR: Chen Sibao; Singh Jagdish
CORPORATE SOURCE: Department of Pharmaceutical Sciences, College of Pharmacy, Nursing, and Allied Sciences, North Dakota State University, Fargo, ND 58105, USA.
CONTRACT NUMBER: HD4137 (United States NICHD NIH HHS)
SOURCE: International journal of pharmaceutics, (2008 Mar 20) Vol. 352, No. 1-2, pp. 58-65. Electronic Publication: 2007-10-22.
Journal code: 7804127. ISSN: 0378-5173.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200807
ENTRY DATE: Entered STN: 27 Feb 2008
Last Updated on STN: 23 Jul 2008
Entered Medline: 22 Jul 2008
AB The purpose of this study was to design injectable controlled release polymer formulations for growth hormone using triblock copolymer PLGA-PEG-PLGA (MW 1400-1000-1400). Porcine growth hormone (pGH) formulations were prepared by adding pGH into 30% (w/v) aqueous solution of triblock copolymer. pGH concentrations in the released samples were determined using a standard MicroBCA method. In vitro release studies demonstrated that there were no initial burst of pGH from both formulations containing a low dose (0.12%, w/v) and a high dose (0.42%, w/v) of pGH. In vivo absorption study of pGH in rabbits showed that constant serum levels of exogenous pGH (3-7 ng/mL from high dose and 2-4 ng/mL from low dose) were detected for nearly 4 weeks from delivery systems upon single subcutaneous injection. The absolute bioavailability of pGH enhanced from the thermosensitive polymer-based systems, which was approximately 5-15-fold those of subcutaneous aqueous solution. MTT assay and light microscopy were used to investigate the in vitro and in vivo biocompatibility of thermosensitive polymer delivery systems, respectively. Both in vitro and in vivo results support the biocompatible nature of these polymer delivery systems. Thus, the triblock copolymer used in this study was able to control the release of incorporated pGH in vitro and in vivo for longer duration and the delivery system was biocompatible.

L3 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1127506 CAPLUS
DOCUMENT NUMBER: 149:340028
TITLE: Pharmaceutical compositions containing human growth hormone
INVENTOR(S): Patel, Ashish Binpin; Azria, Moise; Li, Shoufeng
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008112836	A2	20080918	WO 2008-US56757	20080313
WO 2008112836	A3	20081204		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-894961P P 20070315

AB The invention pertains to a suppository that enables the successful delivery of human growth hormone (hGH), to a subject via administration of the suppository and provides pharmaceutical compns. which are suppositories comprising a human growth hormone as the active ingredient together with the delivery agent 5-CNAC, where the pharmaceutical provides bioavailability, e.g. satisfactory or optimal rectal bioavailability for the human growth hormone active ingredient. Using a 96% PEG-1000, 4% PEG-4000, and a cocoa butter base, hGH was absorbed at therapeutic levels by using 5-CNAC in Rhesus monkeys.

L3 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:771340 CAPLUS
DOCUMENT NUMBER: 149:87638
TITLE: Human growth hormone formulations
INVENTOR(S): Chung, Wen-Li; Bush, Lawrence; Pechenov, Sergey; Basu, Sujit K.
PATENT ASSIGNEE(S): Altus Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 145pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076819	A2	20080626	WO 2007-US87417	20071213
WO 2008076819	A3	20090326		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2006-870605P P 20061218

AB Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins. Thus, a human growth hormone formulation comprised human growth hormone derivative crystals at 5-50 mg/mL, phosphate buffer at pH of 6.1-6.8, sodium chloride or sodium acetate at 60-200 mM, 2.5-20% PEG, with the formulation being disposed in a siliconized prefiled syringe with no more than 10 mm head space; and a volume of 0.2-1.0 mL.

L3 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:223214 CAPLUS
DOCUMENT NUMBER: 148:278902
TITLE: Streptoverticillium transglutaminase variants with improved specificity towards human growth hormone, and use for the preparation of pharmaceutical compositions
INVENTOR(S): Hu, Zhixiang; Zhao, Xin; Wang, Jianhua; Chang, Chih-Chuan; Noerskov-Lauritsen, Leif
PATENT ASSIGNEE(S): Novo Nordisk Health Care A.-G., Switz.
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020075	A1	20080221	WO 2007-EP58571	20070817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2007020290	A1	20070222	WO 2006-EP65439	20060818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
EP 2054436 A1 20090506 EP 2007-802683 20070817
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
WO 2008102007 A1 20080828 WO 2008-EP52190 20080222
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
WO 2008102008 A1 20080828 WO 2008-EP52194 20080222
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: WO 2006-EP65439 A 20060818
EP 2007-102885 A 20070222
EP 2007-102886 A 20070222
EP 2005-107599 A 20050818
WO 2007-EP58571 W 20070817

AB Variants of transglutaminase from Streptoverticillium ladakanum and S. mobaraense, which variants have improved selectivity for Gln-141 of human growth hormone (hGH) are provided. The transglutaminase variants with improved selectivity are used for conjugating hGH at Gln-141. The conjugated hGH is used for the preparation of PEGylated hGH for the use in pharmaceutical compns. for treating hGH-associated diseases.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1129938 CAPLUS
DOCUMENT NUMBER: 149:363068
TITLE: Ceramic implant composition comprising bioactive glass particles in glycerol/polyethylene glycol carrier aqueous solution, for filling bone defects
INVENTOR(S): Depaula, Carl Alexander
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20080226688	A1	20080918	US 2007-724255	20070315
CA 2582551	A1	20080915	CA 2007-2582551	20070322
CN 101264340	A	20080917	CN 2007-10185030	20071106

PRIORITY APPLN. INFO.: US 2007-724255 A 20070315

AB The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (weight/weight), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (weight/weight) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35. Thus, putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62 wt%) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14 wt%) with 2.4 g of carrier (24 wt%) made up of glycerol and PEG having a mol. weight of 2000 in a ratio of 60:40; the composition had a total glass percentage (76 wt%) forming a putty which was acceptable.

L3 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:548987 CAPLUS
DOCUMENT NUMBER: 148:546092
TITLE: Sustained-release fine particle compositions and their manufacture
INVENTOR(S): Nagao, Takeshi; Miyamoto, Yoko; Niimi, Jun
PATENT ASSIGNEE(S): Galeni Search Laboratories, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008106024	A	20080508	JP 2006-292936	20061027

PRIORITY APPLN. INFO.: JP 2006-292936 20061027

AB Title compns. comprise are manufactured by mixing aqueous solns. of water-soluble divalent metal compds. with protein pharmaceuticals adsorbed into porous hydroxyapatite derivative fine particles at absorption rate 40-80%, freeze-drying, aqueous solns. or suspensions of hydrophilic biodegradable polymers, then freeze- or vacuum-drying. Thus, Zn-substituted hydroxyapatite was mixed with aqueous human growth hormone (hGH) and buffer solution, centrifuged, supernatant removed, mixed with aqueous ZnCl2, freeze-dried, mixed with aqueous acetone solution of poly(lactic acid)-polyethylene glycol-poly(lactic acid) bock copolymer, and freeze-dried to give fine powder composition, which released 5.2% hGH to phosphate buffer physiol. saline in 5 h.

L3 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:538036 CAPLUS
DOCUMENT NUMBER: 148:592937
TITLE: Pharmaceutical compositions containing the conjugates of polyethylene glycol with oligopeptide and proteins
INVENTOR(S): Zhao, Xuan; Gu, Qiang
PATENT ASSIGNEE(S): Beijing Jiankai Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 23pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101168594	A	20080430	CN 2006-10150011	20061024
WO 2008052428	A1	20080508	WO 2007-CN3030	20071024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: CN 2006-10150011 A 20061024

GI



AB The title compound formed from polyethylene glycol and oligopeptide/protein can be expressed as formula I, (PEGi-Xi)j-A-(Fp)q, in which i = 1-j integer; j = >= 2 integer; and Xi can be the same or not connecting group; A comes from oligopeptide containing 2-20 amino acids, wherein at least two amino acids are different; and Fp is the active group selected from hydroxyl, acryl chloride, carboxyl, ester, acyl, hydrazide, maleimide, and pyridine disulfide; P is 1-q integer. The obtained compound can bond with proteins or polypeptides of macromol. or natural pharmaceutical active components via Fp to improve in-vivo physiol. function of pharmaceutical mols. or maintain pharmaceutical concentration and supply sustained-release function.

L3 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:538922 CAPLUS
DOCUMENT NUMBER: 146:487803
TITLE: Human growth hormone patch formulations
INVENTOR(S): Sacks, Hagit; Stern, Meir
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.; Transpharma Medical Ltd.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056105	A2	20070518	WO 2006-US42894	20061102
WO 2007056105	A3	20070705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,

RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2634181	A1	20070518	CA 2006-2634181	20061102
US 20070141132	A1	20070621	US 2006-592791	20061102
EP 1948221	A2	20080730	EP 2006-836849	20061102
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009514869	T	20090409	JP 2008-539045	20061102
US 20080226703	A1	20080918	US 2008-92239	20080430
PRIORITY APPLN. INFO.:			US 2005-733005P P	20051102
			US 2005-739288P P	20051122
			WO 2006-US42894 W	20061102

AB The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of 5 to 9 and the formulation does not contain both glycine and mannitol. For example, a transdermal patch formulation contained hGH, sucrose, and glycine in a phosphate buffer, wherein the concentration ratio of hGH, sucrose, and glycine is 0.85:0.8:0.26 to 0.85:1.20:0.40.

L3 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:703724 CAPLUS
DOCUMENT NUMBER: 147:150948
TITLE: Liquid formulation comprising human growth hormone whose deamidation and agglutination are minimized
INVENTOR(S): Kim, Sun Hee; Chung, Yo Kyung; Chang, Jae Young; Lee, Sang Kil; Lee, Min Suk; Park, Seung Kook; Lee, Bong Yong
PATENT ASSIGNEE(S): Daewoong Co., Ltd., S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2006124449	A	20061205	KR 2005-46381	20050531
KR 769709	B1	20071023		
WO 2008004717	A1	20080110	WO 2006-KR2640	20060706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2049148	A1	20090422	EP 2006-769186	20060706
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				

BA, HR, MK, RS

PRIORITY APPLN. INFO.: KR 2005-46381 T0 20050531
WO 2006-KR2640 W 20060706

AB A liquid formulation containing human growth hormone is provided to enhance storage stability by minimizing deamidation and agglutination of human growth hormone. The liquid formulation contains: human growth hormone; L-lysine or L-arginine; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethyleneglycol-15 polyoxystearate or polyethyleneglycol-35 castor oil, wherein the amount of human growth hormone is 2.5-5.5 mg/mL, the amount of L-lysine or L-arginine is 0.02-0.5 w/v% per 1 mg of human growth hormone, and the amount of poly(oxyethylene) poly(oxypropylene) copolymer, polyethyleneglycol-15 polyoxystearate or polyethyleneglycol-35 castor oil is 0.1-0.5 w/v%; and the liquid formulation further contains at least one component selected from buffer solution, tonicity adjustment agent, preservative and analgesia.

L3 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:612122 CAPLUS
DOCUMENT NUMBER: 143:120561
TITLE: Stable growth hormone liquid formulation
INVENTOR(S): Badkar, Advait; Nema, Sandeep; Wadhwa, Manpreet
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063298	A1	20050714	WO 2004-IB4159	20041213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2551510	A1	20050714	CA 2004-2551510	20041213
EP 1706150	A1	20061004	EP 2004-801396	20041213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004018115	A	20070417	BR 2004-18115	20041213
JP 2007516274	T	20070621	JP 2006-546366	20041213
MX 2006006535	A	20060731	MX 2006-6535	20060608
US 20080125356	A1	20080529	US 2007-583923	20070514

PRIORITY APPLN. INFO.: US 2003-531843P P 20031223
WO 2004-IB4159 W 20041213

AB The present invention is directed to stable liquid growth hormone formulations that remain stable after phys. agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temps., even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human

growth hormone).
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:451425 CAPLUS
DOCUMENT NUMBER: 143:13190
TITLE: A pharmaceutical composition comprising a recombinant nonglycosylated immunoglobulin Fc region conjugated to a therapeutic protein as a drug carrier
INVENTOR(S): Kim, Young Min; Song, Dae Hae; Jung, Sung Youb; Kim, Chang Hwan; Choi, In Young; Kwon, Se Chang; Lee, Gwan Sun
PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047337	A1	20050526	WO 2004-KR2945	20041113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005047030	A	20050519	KR 2004-92780	20041113
KR 2005047031	A	20050519	KR 2004-92781	20041113
KR 775343	B1	20071108		
KR 2005047032	A	20050519	KR 2004-92782	20041113
KR 2005047033	A	20050519	KR 2004-92783	20041113
CA 2512933	A1	20050526	CA 2004-2512933	20041113
AU 2004282985	A1	20050630	AU 2004-282985	20041113
AU 2004282985	B2	20080814		
AU 2004282984	A1	20050714	AU 2004-282984	20041113
BR 2004006606	A	20051206	BR 2004-6606	20041113
CN 1723219	A	20060118	CN 2004-80001770	20041113
CN 1723220	A	20060118	CN 2004-80001775	20041113
EP 1682584	A1	20060726	EP 2004-800092	20041113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007537992	T	20071227	JP 2006-539399	20041113
RU 2352583	C2	20090420	RU 2005-120239	20041113
IN 2005DN02857	A	20070525	IN 2005-DN2857	20050627
MX 2005007211	A	20060210	MX 2005-7211	20050630
KR 2006054252	A	20060522	KR 2006-36697	20060424
US 20060275254	A1	20061207	US 2006-535231	20060724

PRIORITY APPLN. INFO.:		
KR 2003-80299	A	20031113
KR 2004-92780	A3	20041113
WO 2004-KR2945	W	20041113

AB Disclosed is a novel use of an Ig Fc fragment, and more particularly, a pharmaceutical composition comprising an Ig Fc fragment as a carrier. Most preferable Ig Fc fragment is a human IgG4-derived nonglycosylated Fc

fragment produced by a prokaryote, preferably E. coli. Also demonstrated are preparation and pharmacokinetic anal. of α interferon (hIFNα-2b), human growth hormone, EPO, G-CSF and Fab' conjugated to various forms of Fc fragments through 3.4 kDa PEG. The pharmaceutical composition comprising an Ig Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the Ig Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:451422 CAPLUS

DOCUMENT NUMBER: 143:13189

TITLE: A pharmaceutical composition comprising aglycosylated IgG Fc fragment as a drug carrier, and method for the preparation thereof

INVENTOR(S): Jung, Sung Youb; Kim, Jin Sun; Yang, Geun Hee; Kwon, Se Chang; Lee, Gwan Sun

PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047334	A1	20050526	WO 2004-KR2942	20041113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005047030	A	20050519	KR 2004-92780	20041113
KR 2005047031	A	20050519	KR 2004-92781	20041113
KR 775343	B1	20071108		
KR 2005047032	A	20050519	KR 2004-92782	20041113
KR 2005047033	A	20050519	KR 2004-92783	20041113
AU 2004282984	A1	20050714	AU 2004-282984	20041113
CN 1723219	A	20060118	CN 2004-80001770	20041113
CN 1723220	A	20060118	CN 2004-80001775	20041113
EP 1682581	A1	20060726	EP 2004-800089	20041113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007531513	T	20071108	JP 2006-539396	20041113
KR 2006054252	A	20060522	KR 2006-36697	20060424
US 20070041967	A1	20070222	US 2006-535341	20060609

PRIORITY APPLN. INFO.:

KR 2003-80299	A	20031113
KR 2004-92780	A3	20041113
WO 2004-KR2942	W	20041113

AB Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the

present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. Preferably aglycosylated IgG2 Fc and IgG4 Fc fragments are used. Provided are sequences for IgG Fc fragments and Fc fragments-encoding genes. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug. Demonstrated is preparation of GH-, G-CSF-PEG-Fc conjugates and INFα-PEG-deglycosylated Fc conjugates. Also demonstrated are changes in pharmacokinetics, cytotoxicity and activity of α interferon, human growth hormone and G-CSF.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:346886 CAPLUS
DOCUMENT NUMBER: 142:379425
TITLE: Long-acting modified proteins used in sustained release formulations for reduced clearance
INVENTOR(S): Jensen, Simon Bjerregaard; Iversen, Lars Fogh; Rischel, Christian; Reslow, Mats
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005034988	A1	20050421	WO 2004-DK684		20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1677819	A1	20060712	EP 2004-762903		20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007508250	T	20070405	JP 2006-529652		20041008
US 20060257479	A1	20061116	US 2006-395770		20060331
PRIORITY APPLN. INFO.:			DK 2003-1496	A	20031010
			US 2003-510892P	P	20031014
			WO 2004-DK684	W	20041008

AB Sustained release formulations comprising mols. modified so as to have a reduced clearance are provided. For example, human growth hormone conjugated with PEG used in sustained formulations containing hydrophobic polymers, such as PEG, and PGLA.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:283354 CAPLUS

DOCUMENT NUMBER: 142:322803
TITLE: Liquid human growth hormone formulation containing polyethylene glycol
INVENTOR(S): Williams, Ashley Martin; Sereda, Terrance Jimmy; Wiebe, Deanna June
PATENT ASSIGNEE(S): Cangene Corporation, Can.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005027960	A1	20050331	WO 2004-CA1698		20040927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2540172	A1	20050331	CA 2004-2540172		20040927
EP 1663296	A1	20060607	EP 2004-761854		20040927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007506683	T	20070322	JP 2006-527240		20040927
US 20090029911	A1	20090129	US 2007-573571		20070322
PRIORITY APPLN. INFO.:			US 2003-505432P	P	20030925
			WO 2004-CA1698	W	20040927

AB A stable pharmaceutically acceptable aqueous formulation contains human growth hormone, a buffer, polyethylene glycol, a tonicifier such as a sugar alc., and optionally, an antimicrobial agent and optionally, a chelating agent. Also disclosed are associated means and methods for preparing, storing and using such formulations.thus, a formulation containing PEG, buffer, tonicifying agent, protected the hGH against both phys. and chemical degradation during long-term storage.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:55083 CAPLUS
DOCUMENT NUMBER: 142:141264
TITLE: Compositions and methods for enhanced mucosal delivery of growth hormone
INVENTOR(S): Quay, Steven C.; De Meireles, Jorge C.; Gupta, Malini; Vangala, Shyam
PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004895	A2	20050120	WO 2004-US17632	20040601
WO 2005004895	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2528465	A1	20050120	CA 2004-2528465	20040601
US 20050031549	A1	20050210	US 2004-862141	20040601
EP 1643970	A2	20060412	EP 2004-754279	20040601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007500243	T	20070111	JP 2006-533559	20040601
MX 2005013340	A	20060309	MX 2005-13340	20051208

PRIORITY APPLN. INFO.:	US 2003-477403P	P	20030609
	WO 2004-US17632	W	20040601

AB Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of growth hormone to the blood plasma, for example, by yielding a peak concentration (Cmax) of the growth hormone in an hepatic portal vein or a blood plasma of the subject that is 20% or greater compared to a peak concentration of the growth hormone in the hepatic portal vein or the blood plasma of the subject following administration to the subject of a same concentration or dose of the growth hormone to the subject by s.c. injection. Exemplary formulations and methods within the invention utilize human growth hormone as the hormone. A composition contained growth hormone, sucrose, phosphate, arginine-HCl, di-Na EDTA, and water.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2005:1334140 CAPLUS
DOCUMENT NUMBER:	144:74823
TITLE:	Human growth hormone conjugated with biocompatible polymer
INVENTOR(S):	Park, Myung-Ok; Jacobs, John W.
PATENT ASSIGNEE(S):	Phage Biotechnology Corporation, USA
SOURCE:	U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Ser. No. 947,513. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050281778	A1	20051222	US 2005-187522	20050722
KR 2004086521	A	20041011	KR 2004-7983	20040206
WO 2004084948	A1	20041007	WO 2004-KR701	20040327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 20050059129	A1	20050317	US 2004-947513	20040922
US 20060134736	A1	20060622	US 2005-314926	20051220
AU 2005335186	A1	20070215	AU 2005-335186	20051220
CA 2616187	A1	20070215	CA 2005-2616187	20051220
WO 2007018583	A2	20070215	WO 2005-US46791	20051220
WO 2007018583	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1915179	A2	20080430	EP 2005-855362	20051220

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

JP 2009502779	T	20090129	JP 2008-522759	20051220
KR 2008041661	A	20080513	KR 2008-704205	20080221

PRIORITY APPLN. INFO.:	KR 2003-19734	A	20030328
	KR 2004-7983	A	20040206
	WO 2004-KR701	A2	20040327
	US 2004-947513	A2	20040922
	US 2005-187522	A2	20050722
	WO 2005-US46791	W	20051220

AB The present invention relates to conjugates of biocompatible polymers and biol. active proteins, such as human growth hormone (hGH), particularly PEG-hGH, where the activated biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 1:1, methods of preparation, and related pharmaceutical compns. The PEG-hGH conjugates have up to 20% of the activity of the native hGH while the in vivo half life is increased 10 fold. The PEG-hGH conjugates may be used therapeutically to treat growth retardation or growth failure, especially short stature in children, and conditions related to aging. Thus, the PEG-hGH conjugate was prepared by reacting hGH with PEG derivs. activated with EDAC. The reaction was carried out for 1 h at 25° using either PEG 20,000 or PEG 30,000. MonoPEG-hGH and diPEG-hGH were obtained and purified by HPLC using a size-exclusion column. Mono- and diPEG-hGH retained 15±5% and 8±2% of biol. activity, resp., as compared to native hGH. However, the PEG-hGH was cleared much slower than native hGH in rats. Thus, the PEG-hGH samples of this study can provide a new sustained released drug of hGH.

L3 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2006:877511 CAPLUS
DOCUMENT NUMBER:	145:278290
TITLE:	Composition for stabilized liquid formulation of human growth hormone which minimizes deamidation, polymer

formation and oxidative dissociation of human growth hormone(hGH)

INVENTOR(S): Jung, Sung Youb; Kim, Young Min; Kwon, Se Chang; Lee, Gwan Sun; Yang, Geun Hee

PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005023875	A	20050310	KR 2003-61434	20030903

PRIORITY APPLN. INFO.: KR 2003-61434 20030903

AB A composition for stabilized liquid formulation of human growth hormone is provided which minimizes deamidation, polymer formation and oxidative dissociation of human growth hormone(hGH). The stability of the liquid formulation was improved. The composition for stabilized liquid formulation of human growth hormone comprises 1 to 10 mg/mL human growth hormone(hGH), 5 to 100 mM buffering agent, 0.001 to 20 mg/mL polyethylene glycol and 5 to 100 mg/mL tonicity adjustment agent, wherein the human growth hormone is recombinant methionyl human growth hormone or recombinant natural human growth hormone; the buffering agent is sodium citrate; the tonicity adjustment agent comprises sodium chloride, mannitol and a mixture thereof; and the composition has pH 5.5 to 6.5.

L3 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:901684 CAPLUS

DOCUMENT NUMBER: 144:27270

TITLE: Novel Long-Acting Crystal Formulation of Human Growth Hormone

AUTHOR(S): Govardhan, Chandrika; Khalaf, Nazer; Jung, Chu W.; Simeone, Ben; Higbie, Amy; Qu, Susan; Chemmalil, Letha; Pechenov, Sergey; Basu, Sujit K.; Margolin, Alexey L.

CORPORATE SOURCE: Altus Pharmaceuticals Inc., Cambridge, MA, 02139, USA

SOURCE: Pharmaceutical Research (2005), 22(9), 1461-1470
CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Springer Science+Business Media, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of the study is to solve a significant challenge of extending the half-life of therapeutic proteins using crystalline biopharmaceuticals and without redesigning the mols. Crystals of recombinant human growth hormone were coated with a monomol. layer of pos. charged poly(arginine). The pharmacokinetics and pharmacodynamics of this poly(arginine)-coated human growth hormone crystalline formulation were determined in hypophysectomized rats and monkeys. Here the authors have demonstrated for the first time that crystals of human growth hormone coated with pos. charged poly(arginine) allowed for in vivo pharmacokinetic release profiles of over several days in animal models. The efficacy of this crystalline formulation injected s.c. once a week was found to be equivalent to 7 daily soluble injections in the standard weight gain assay using the hypophysectomized rat model and in measurement of serum insulin-like growth factor in monkeys. The nonviscous nature of the suspension facilitated easy administration through a fine, 30-gauge needle and should provide for improved patient

convenience and compliance. The approach described here offers an exciting possibility of being broadly applicable to other therapeutic proteins.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1033550 CAPLUS
DOCUMENT NUMBER: 142:33306
TITLE: Methods and compositions for the preparation of human growth hormone (hCG) glycosylation mutants with reduced immunogenicity, and therapeutic uses thereof
INVENTOR(S): Clausen, Henrik
PATENT ASSIGNEE(S): Neose Technologies, Inc., USA; Defrees, Shawn
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004103275	A2	20041202	WO 2004-US14254		20040507
WO 2004103275	A3	20070518			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA					
AU 2004240553	A1	20041202	AU 2004-240553		20040507
CA 2524936	A1	20041202	CA 2004-2524936		20040507
EP 1624847	A2	20060215	EP 2004-751591		20040507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004010164	A	20060516	BR 2004-10164		20040507
JP 2007523630	T	20070823	JP 2006-532844		20040507
CN 101080238	A	20071128	CN 2004-80016847		20040507
ZA 2005009864	A	20080227	ZA 2005-9864		20040507
MX 2005011832	A	20060217	MX 2005-11832		20051103
KR 2006030023	A	20060407	KR 2005-721304		20051109
IN 2005KN02351	A	20060825	IN 2005-KN2351		20051123
US 20080102083	A1	20080501	US 2007-556094		20070416
PRIORITY APPLN. INFO.:			US 2003-469114P	P	20030509
			US 2003-494751P	P	20030813
			US 2003-495076P	P	20030814
			US 2004-535290P	P	20040108
			WO 2004-US14254	W	20040507

AB The present invention relates to mutants of human growth hormone, which contain newly introduced N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compns. comprising the mutants and method for

using the mutants.

L3 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:589380 CAPLUS
DOCUMENT NUMBER: 141:128854
TITLE: Human growth hormone crystals and methods for preparing them
INVENTOR(S): Govardhan, Chandrika; Khalaf, Nazer; Simeone, Benjamin Paul
PATENT ASSIGNEE(S): Altus Biologics Inc., USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060310	A2	20040722	WO 2003-US41545	20031231
WO 2004060310	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2512052	A1	20040722	CA 2003-2512052	20031231
AU 2003303646	A1	20040729	AU 2003-303646	20031231
US 20040209804	A1	20041021	US 2003-749962	20031231
EP 1581251	A2	20051005	EP 2003-808602	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017888	A	20051206	BR 2003-17888	20031231
CN 1744914	A	20060308	CN 2003-80109408	20031231
JP 2006512416	T	20060413	JP 2005-508635	20031231
ZA 2005005305	A	20070725	ZA 2005-5305	20031231
RU 2357750	C2	20090610	RU 2005-124280	20031231
IN 2005KN01264	A	20070309	IN 2005-KN1264	20050629
MX 2005007181	A	20060407	MX 2005-7181	20050630
IN 2008KN02347	A	20090123	IN 2008-KN2347	20080611

PRIORITY APPLN. INFO.:		
US 2002-437519P	P	20021231
US 2003-517042P	P	20031103
WO 2003-US41545	W	20031231
IN 2005-KN1264	A3	20050629

AB The present invention relates to stable, extended release crystals of human growth hormone (hGH) or a human growth hormone derivative and compns. or formulations comprising such crystals. The invention further provides methods for producing those crystals and compns. The invention further provides methods for treatment of an individual having disorders associated with human growth hormone deficiency or which are ameliorated by treatment with human growth hormone using those crystals and compns. or formulations. For example, crystallization of hGH with calcium acetate, PEG-6000 and protamine sulfate was carried out. Com. available hGH was purified and concentrated, and deionized water was added to the concentrated hGH solution to yield a final protein concentration of 15 mg/mL. Tris-HCl (1 M, pH 8.6) was added to a

final concentration of 100 mM. To this solution, protamine sulfate (1 mg/mL) and 6%
PEG-6000 (volume/volume) was added. Crystals of hGH were grown by adding calcium acetate (1 M) to the solution so that a final concentration of 85 mM calcium
acetate was obtained. The solution was then incubated for 16 h at 37°. Needle-like crystals obtained were found to be less than 25 μm in length with a crystallization yield of > 70%.
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:955600 CAPLUS
DOCUMENT NUMBER: 142:204674
TITLE: Biodegradable pharmaceutical composition enabling sustained release of human growth hormone and microsphere thereof
INVENTOR(S): Cho, Yeong U.; Kim, Hong Gi; Kim, Won Bae; Lee, Geon Il; Lee, Seong Hui; Park, Tae Gwan; Park, Yong Man
PATENT ASSIGNEE(S): Dong-A Pharm. Co., Ltd., S. Korea; Korea Advanced Institute of Science and Technology
SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2003006455	A	20030123	KR 2001-42196	20010713
KR 838219	B1	20080613		
PRIORITY APPLN. INFO.:			KR 2001-42196	20010713

AB A microsphere containing a drug obtained by adding polyethylene glycol as a protein stabilizer in an appropriate ratio and then including human growth hormone into the microsphere is provided which enables the human growth hormone to continuously release from the microsphere for two weeks even in vivo as well as in vitro. The microspherical composition contains human growth hormone, polyethylene glycol or a derivative thereof as a protein stabilizer, a biodegradable polyester polymer as a polymer carrier, a surfactant and an emulsifier, wherein the human growth hormone and polyethylene glycol or a mixture thereof are dispersed in a droplet of the surfactant to form a first emulsion. The first emulsion is dispersed in the droplet of the emulsion.

L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:171688 CAPLUS
DOCUMENT NUMBER: 136:221723
TITLE: Sustained release formulations for growth hormone secretagogues
INVENTOR(S): Am Ende, Mary Tanya; Curatolo, William John; Herbig, Scott Max
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002017918	A2	20020307	WO 2001-IB1429	20010808
WO 2002017918	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420535	A1	20020307	CA 2001-2420535	20010808
AU 2001076608	A	20020313	AU 2001-76608	20010808
EP 1313473	A2	20030528	EP 2001-954267	20010808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013626	A	20030617	BR 2001-13626	20010808
JP 2004507502	T	20040311	JP 2002-522891	20010808
US 20020137765	A1	20020926	US 2001-940097	20010827
US 6641840	B2	20031104		
MX 2003001771	A	20030604	MX 2003-1771	20030227
US 20040091530	A1	20040513	US 2003-611586	20030630

PRIORITY APPLN. INFO.:	US 2000-229074P	P	20000830
	WO 2001-IB1429	W	20010808
	US 2001-940097	A3	20010827

AB The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation. Thus, a sustained release dosage form for oral administration contained 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxoethyl]isobutyramide L-tartrate 3.89, mannitol 34.00, fumaric acid 12.00, microcryst. cellulose 48.61, Mg stearate 1.50, cellulose acetate 11.90, and PEG 5.10 mg/tablet.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:869417 CAPLUS
DOCUMENT NUMBER:	137:358174
TITLE:	Optimization of the molecular properties and formulation of proteins delivered by inhalation by pegylation or glycosylation
INVENTOR(S):	Gonda, Igor
PATENT ASSIGNEE(S):	Australia
SOURCE:	U.S. Pat. Appl. Publ., 6 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020168323	A1	20021114	US 2002-146549	20020513
CA 2445494	A1	20021121	CA 2002-2445494	20020513

WO 2002092147 A2 20021121 WO 2002-US15429 20020513
WO 2002092147 A3 20031127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002309848 A1 20021125 AU 2002-309848 20020513
EP 1392350 A2 20040303 EP 2002-736873 20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004531550 T 20041014 JP 2002-589063 20020513
PRIORITY APPLN. INFO.: US 2001-290292P P 20010511
WO 2002-US15429 W 20020513

AB Pegylation or glycosylation of therapeutic proteins enhances at least one of the solubility, stability and bioavailability, for delivery of an effective amount in an aerosol delivery to the lungs using a minimal number of puffs. E.g., the optimum pegylated derivative of recombinant human growth hormone is one that can be delivered in the min. number of breaths from a system such as AERx or Respimat.

L3 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:713164 CAPLUS
DOCUMENT NUMBER: 135:262256
TITLE: A somatotropin composition with improved syringeability
INVENTOR(S): Kim, Nam Joong; Ryoo, Je Phil
PATENT ASSIGNEE(S): Lg Chemical Ltd., S. Korea
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070256	A1	20010927	WO 2000-KR1151	20001016
W: AU, BR, CA, MX, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 2001089862	A	20011012	KR 2000-15091	20000324
CA 2374043	A1	20010927	CA 2000-2374043	20001016
BR 2000010947	A	20020312	BR 2000-10947	20001016
EP 1194160	A1	20020410	EP 2000-970270	20001016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 783240	B2	20051006	AU 2000-79671	20001016
EG 24204	A	20081020	EG 2001-295	20010324
MX 2001011719	A	20030910	MX 2001-11719	20011114
US 6733786	B1	20040511	US 2001-926590	20011121

PRIORITY APPLN. INFO.: KR 2000-15091 A 20000324
WO 2000-KR1151 W 20001016

AB An improved composition consists of somatotropin with activity in vivo, a lipid-soluble vitamin and at least 1 lubricant. This improves the poor syringeability under cold temps. of the conventional somatotropin formulation. Thus, bovine somatotropin solution was lyophilized and the

powder obtained was mixed with vitamin E acetate and benzyl alc. The above composition was filled in a polypropylene syringe and the sample was stored at ambient temperature and 4°.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:843144 CAPLUS
DOCUMENT NUMBER: 142:11539
TITLE: Sustained releasing composition comprising somatotropin
INVENTOR(S): Kim, Nam Joong; Joh, Heung Soo; Lee, Byung Kum
PATENT ASSIGNEE(S): LG Chemical Co., Ltd., S. Korea
SOURCE: Repub. Korea, No pp. given
CODEN: KRXXFC
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 143767	B1	19980715	KR 1991-24288	19911224

PRIORITY APPLN. INFO.: KR 1991-24288 19911224

AB An implantable formula containing somatotropin is provided for sustained release of somatotropin that promotes animal's growth. A process for the preparation of sustained releasing formula containing somatotropin comprises of:
mixing polyethylene glycol, the water-soluble polymer with somatotropin or liposome bovine somatotropin; adding some water and mixing; granulation; coating granulated compound by spraying hydroxy Pr cellulose dissolved in ethanol using spray gun; making tablet or pellet by tablet machine.

L3 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:958515 CAPLUS
DOCUMENT NUMBER: 123:350357
ORIGINAL REFERENCE NO.: 123:62653a,62656a
TITLE: Wound healing compositions containing cell culture medium and growth hormones
INVENTOR(S): Lindenbaum, Ella
PATENT ASSIGNEE(S): Life Medical Science, Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5461030	A	19951024	US 1993-158808	19931129
US 5591709	A	19970107	US 1995-374944	19950118

PRIORITY APPLN. INFO.:
IL 1991-97127 A 19910201
US 1991-752849 B1 19910830
US 1992-937486 B2 19920828
US 1993-25216 B2 19930302
US 1993-158808 A2 19931129

AB The title formulations are useful for treating wounds by accelerating wound healing. These formulations comprise an effective amount of a serum free cellular nutrient medium in combination with an effective amount of at least one cellular growth stimulating compound, e.g. a natural anabolic hormone or transforming growth factor. Thus, 100 g of lyophilized powder

of MCDB 153 culture medium was reconstituted with water and supplemented with human growth hormone to final concentration of 0.5-2 ng/mL. In certain formulations insulin-transferrin was added to final concentration of 5μg/mL and collagen or gelatin at 4% concentration The compns. were effective in treatment of pressure wound and skin ulcers.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:307496 CAPLUS
DOCUMENT NUMBER: 120:307496
ORIGINAL REFERENCE NO.: 120:53945a,53948a
TITLE: Sustained-release protein formulations with PEG and triacetin
INVENTOR(S): Hageman, Michael J.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9406452	A1	19940331	WO 1993-US7756	19930823
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9350186	A	19940412	AU 1993-50186	19930823
EP 661989	A1	19950712	EP 1993-920157	19930823
EP 661989	B1	19970806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08501305	T	19960213	JP 1994-508083	19930823
JP 3756512	B2	20060315		
AT 156361	T	19970815	AT 1993-920157	19930823
ES 2107051	T3	19971116	ES 1993-920157	19930823
ZA 9306415	A	19950228	ZA 1993-6415	19930831
US 6011011	A	20000104	US 1995-407327	19950320
JP 2004285079	A	20041014	JP 2004-206098	20040713

PRIORITY APPLN. INFO.:

US 1992-947872	A2	19920921
US 1992-963365	A2	19921020
JP 1994-508083	A3	19930823
WO 1993-US7756	W	19930823

AB Novel sustained-release injections of a protein or peptide, e.g. somatotropin (I) and growth hormone releasing factor, are prepared using triacetin or PEG. Thus, 25.01 g triacetin was mixed with 6.85 g bovine somatotropin to obtain a suspension containing 200mg I/mL. Cows were injected s.c. with 0.7mL of the suspension containing 150 mg I. The greatest quantity of I appeared in the serum 12-30 h post injection and remained elevated for .apprx.84 hs.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:638406 CAPLUS
DOCUMENT NUMBER: 121:238406
ORIGINAL REFERENCE NO.: 121:43325a,43328a
TITLE: Implantable composition for the controlled release of somatotropin

INVENTOR(S): Kin, Nam Joong; Cho, Heung Soo; Sorig, Maeng Seok; Choi, Yun Jeong; Rhee, Byung Geon
PATENT ASSIGNEE(S): Lucky Ltd., S. Korea
SOURCE: Braz. Pedido PI, 33 pp.
CODEN: BPXXDX
DOCUMENT TYPE: Patent
LANGUAGE: Portuguese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BR 9305261	A	19940705	BR 1993-5261	19931228
AU 9352718	A	19940707	AU 1993-52718	19931223
AU 660119	B2	19950608		
CN 1093597	A	19941019	CN 1993-121466	19931228
US 5662917	A	19970902	US 1996-601275	19960322
PRIORITY APPLN. INFO.:			KR 1992-25904 A	19921228
			US 1993-171533 B1	19931222

AB The implantable composition claimed involves somatotropin, a biocompatible wax and a water-soluble polymer. Thus, 5 g lyophilized porcine somatotropin powder is mixed with 10 g polyethylene glycol (mol. weight 35,000) and 10 g paraffin wax, and the mixture is homogenized and formed into tablets measuring 7 mm in diameter and 6.2 mm in thickness. Each tablet contains 250 mg of the homogenized mixture The product allows for prolonged release of somatotropin with few side effects.

L3 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:456164 CAPLUS
DOCUMENT NUMBER: 119:56164
ORIGINAL REFERENCE NO.: 119:9997a,10000a
TITLE: Oral compositions of proteinaceous medicaments
INVENTOR(S): Desai, Ashok J.
PATENT ASSIGNEE(S): Applied Analytical Industries, Inc., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5206219	A	19930427	US 1991-797221	19911125
PRIORITY APPLN. INFO.:			US 1991-797221	19911125

AB Proteinaceous medicaments (e.g. erythropoietin, insulin, calcitonin) are formulated in a medium containing a polyol pharmaceutical solvent combined as cosolvent with a lipid pharmaceutical solvent. The formulation is adapted for oral administration as a liquid as well as a filled hard or soft gelatin capsule. The preferred polyol solvent is PEG/propylene glycol, and the preferred lipid solvent is oleic acid. A capsule formulation contained (per capsule) insulin 140 IU, dimyristyl phosphatidylcholine 0.047, aprotinin 3.39, hydroxypropyl cellulose-LF 3.76, poly-oxy 40 stearate 3.76, PEG 400 139.8, propylene glycol 15.57, water/citrate buffer (pH adjustment) 8.75, cholesterol 31.2, Tween-80 17.56, egg yolk lecithin 63.1, glyceryl monooleate 27.9, d-α-tocopherol 19.6, and oleic acid 249.1 mg.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:656548 CAPLUS

DOCUMENT NUMBER: 119:256548
ORIGINAL REFERENCE NO.: 119:45649a,45652a
TITLE: Injection formulations containing therapeutic peptides and hormones
INVENTOR(S): Igari, Yasutaka; Yamada, Minoru; Ishiguro, Kyoko
PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05238949	A	19930917	JP 1992-334281	19921215
JP 3730667	B2	20060105		

PRIORITY APPLN. INFO.: JP 1991-347352 A1 19911227

AB A long-lasting peptide injection composition consists of (1) a water-soluble peptide with the body clearance rate ≥ 30 mL/h·kg body weight in the rat, (2) an waxlike polyethylene glycol (average mol. weight 2000-6000), and optional nontherapeutic soluble proteins, and acidic mucopolysaccharides. Thus, 10 mg pig insulin (26.8 units/mg) with the clearance rate 1416 mL/h·kg was dissolved in 5 mL 0.1 N HCl. This solution (0.7 mL) was mixed with 0.7 mL saline containing 4.2 mg polyethylene glycol (average mol. weight 2000) to give an injection composition

L3 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:60783 CAPLUS
DOCUMENT NUMBER: 118:60783
ORIGINAL REFERENCE NO.: 118:10905a,10908a
TITLE: Improved high-impact, antistatic, rubber-modified styrene polymer compositions
INVENTOR(S): Fukuoka, Mamoru; Yoneda, Ryoichi; Yanagisawa, Mitsugi; Kamikura, Masao
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04168138	A	19920616	JP 1990-291921	19901031

PRIORITY APPLN. INFO.: JP 1990-291921 19901031

AB The title compns. useful for molding into articles such as housing for elec. appliance, toys, etc. with persistent antistatic properties, are formulated from (A) copolymers derived from styrene-type monomers, unsatd. carboxylic acids, and other comonomers, (B) hydrogenated block polymers containing styrene-type blocks and conjugated diene-type blocks, (C) polyalkylene oxides or their derivs., (D) styrene polymers modified by butadiene rubbers having high degree of cis-1,4-configuration, and (E) antistatic additives. A typical title composition comprised, as A, the emulsion-polymerized styrene-methacrylic acid copolymer 20, as B, Tuftex M-1913 6, as C, a polyethylene glycol 10, as D, Dic Styrene GH-9650 74, and as E, Duspar 802D (alkylsulfonate salt antistatic agent) 2 parts.

L3 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:58404 CAPLUS
DOCUMENT NUMBER: 108:58404
ORIGINAL REFERENCE NO.: 108:9733a,9736a
TITLE: Toilet-cleaning compositions containing polyethylene glycols and ethylene oxide-propylene oxide copolymers
INVENTOR(S): Kunimura, Etsuo
PATENT ASSIGNEE(S): Takasago Perfumery Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62197494	A	19870901	JP 1986-38166	19860225

PRIORITY APPLN. INFO.: JP 1986-38166 19860225
AB The title compns. show minimal changes in viscosity with temperature during summer. Polyethylene glycol (mol. weight 3000-4000, solidification point 53-56°) 63, ethylene oxide-propylene oxide copolymer (Adeka Carpol GH-10) 20, polyethylene glycol (mol. weight 7000-9000, solidification point 58-63°) 8, blue dye 4, and perfume 5% were blended under heat (from 80° to 60°), added to a container at 53°, and cooled to give a waxlike cleaning composition

L3 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1985:472745 CAPLUS
DOCUMENT NUMBER: 103:72745
ORIGINAL REFERENCE NO.: 103:11713a,11716a
TITLE: Water-based ink compositions for ball point pens
PATENT ASSIGNEE(S): Pilot Ink Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60047082	A	19850314	JP 1983-155297	19830825

PRIORITY APPLN. INFO.: JP 1983-155297 19830825
AB The title compns., which afford good lubrication and give good lines even in high-speed writing, contain a dye, water, and ≥1 compound R1CO2(CH2CH2O)nR (R = H, OCR2; R1, R2 = C11-20 alkyl, alkenyl; n = 3-24). Thus, Acid Phloxine (C.I. 45410) [18472-87-2] 2, Eosine GH (C.I. 45380) [17372-87-1] 3.5, propylene glycol 10, thiodiethylene glycol 10, poly(vinyl alc.) 0.3, phenol 0.4, polyethylene glycol monostearate [9004-99-3] (I) 1, and water 72.8 parts were mixed to prepare a red ink, which afforded good writing lines at high speed compared with inferior properties for an ink composition without I.

L3 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:541296 CAPLUS
DOCUMENT NUMBER: 87:141296
ORIGINAL REFERENCE NO.: 87:22283a,22286a
TITLE: Long-acting somatostatin composition
INVENTOR(S): Fenichel, Richard L.; Levin, Howard J.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 3 pp.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4041155	A	19770809	US 1974-518650	19741029

PRIORITY APPLN. INFO.: US 1974-518650 19741029

AB Growth-hormone-release-inhibiting compns. with prolonged action containing Somatostatin [38916-34-6] (a cyclic disulfide tetradecapeptide) or a linear somatostatin (the reduced tetradecapeptide) are prepared by dissolving the drug in water, followed by adding sufficient polyethylene glycol 400 [25322-68-3] or polyethylene glycol 300 to make .apprx.80% of the composition Thus, a formulation containing 500 mg of the cyclic tetradecapeptide/mL was prepared by dissolving 500 mg of it in 0.2 mL water and adding, with stirring, 0.8 mL polyethylene glycol 400. The prolongation of the inhibition of growth hormone release by the formulation was demonstrated when it was injected s.c. into rats.

=> Log Off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:46:47 ON 14 JUL 2009